the goop podcast Histotripsy: Changing How We Treat Cancer
Feb 17, 2026
Mike Blue, CEO of HistoSonics, leads development of histotripsy, a noninvasive focused-ultrasound method to destroy tumors. He explains how the tech works, the FDA-cleared liver treatment, and plans for kidney, pancreas, and other targets. They discuss patient comfort, quality-of-life benefits, immune effects, and where this approach might fit into cancer care.
AI Snips
Chapters
Transcript
Episode notes
Immediate Symptom Relief Reported
- Patients often report immediate pain relief after histotripsy because liquefaction reduces tumor pressures.
- Many advanced-stage patients self-refer after finding others' success stories online.
Early Detection Meets Minimal Treatment
- Histotripsy could shift 'watch and wait' toward immediate non-invasive treatment for tiny nodules.
- Early detection plus safe treatment might prevent downstream costly procedures.
Targetability Limits And Lung Challenges
- Histotripsy requires a physical target; treating blood-borne disease is more challenging.
- Lungs pose complexity due to air blocking ultrasound, but most organs remain technically reachable.